Aaron Cowen’s Alexion Pharmaceuticals ALXN Stock Holding History

Aaron Cowen’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-551,418	Closed	-$49.5M	–	107
2020 Q1	$49.5M	Buy	+551,418	New	+$54.1M	1.34%	27

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aaron Cowen's ALXN Position: Q2 2020 in Review

Aaron Cowen sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 551,418 shares — an estimated $49.5M sold.

Aaron Cowen first reported a position in ALXN in Q1 2020 and held it in 1 quarter. The position peaked at $49.5M in Q1 2020. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Aaron Cowen reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Aaron Cowen sold 551,418 Alexion Pharmaceuticals shares in Q2 2020, an estimated $49.5M.
Aaron Cowen first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Aaron Cowen's Alexion Pharmaceuticals position peaked at $49.5M in Q1 2020.
706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Suvretta Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.